English | 简体中文 | 繁體中文 | 한국어 | 日本語
2022年5月12日 16時00分 JST
Share:
    

Source: Agilex Biolabs
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory

Thebarton, Australia, May 12, 2022 - (JCN Newswire) - Agilex Biolabs Pty Ltd has unveiled its new building with a ribbon cutting ceremony by The Honourable Stephen Patterson MP Minister for Trade and Investment at 12:30pm on Thursday 17 February 2022 at 31 Dalgleish street Thebarton South Australia 5031.

Agilex Biolabs launched its new laboratory for the analysis of large molecule therapeutics, more than doubling the geographic area of its Adelaide campus. The addition of this 2,520 m2 facility expands the service capabilities of Australia's most technologically advanced bioanalytical partner and brings a new point of pride to South Australia.

State-of-the-art instrument platforms and increased capacity empower drug sponsors from all over the world to succeed as they expand into the novel, promising world of large molecule therapeutics. Areas of medicine such as oncology are seeing new ways of approaching treatment due to innovative modalities like antibody-drug conjugates (ADCs) and allogeneic cell therapies. Gene therapies and vaccines created using genetic platforms such as RNA, miRNA, and siRNA need specialised tools and technology to measure critical safety and efficacy endpoints in human clinical trials. The new Agilex large molecule facility features cutting-edge bioanalytical techniques and equipment specifically designed for these fast-growing therapeutic areas, such as digital droplet quantitative RT-PCR analysis and an EliSPOT/FluoroSPOT multi-spot reader for high-sensitivity molecule detection.

Before the new Agilex large molecule facility was built, many drug sponsors conducting clinical trials in Australia would have to ship their clinical samples to labs in other countries to get important patient safety data. The expansion into this kind of support represents South Australia's ability and willingness to accommodate the huge influx of biopharmaceutical companies from all over the world bringing their toxicology studies and clinical programs to Australia.

Adelaide's scientific community can blossom as Agilex Biolab continues to grow. Already staffed with over 150 scientists and support personnel, the comprehensive bioanalytical service headquarters will soon reach 200 welcoming experts from all over the world to its ranks.

"The world's most talented, driven scientists are drawn to research facilities that foster scientific advancement and cutting-edge technology—many of those people will now be coming to Adelaide," said Agilex Biolabs CEO, Jason Valentine. "Committed investment and our local community's support for this new center of scientific excellence will elevate South Australia's reputation for spurring innovation and harboring success."

The community offered their enthusiastic applause at the new facility's official opening on Thursday afternoon. The ribbon cutting ceremony was conducted by the Minister for Trade and Investment, The Honourable Stephen Patterson MP.

Minister for Trade and Investment Stephen Patterson said the State Government had an ambitious plan to grow SA's Health and Medical Industries sector's contribution to the state's economy.

"As a government, we're working collaboratively with industry to more than double the HMI economic contribution to SA from $2.3 billion to $5 billion by 2030.

"South Australia is open for business and at the forefront of world-leading capabilities, bio-tech precincts and an academic research ecosystem that makes it the ideal place to invest and do business."

The traditional 'welcome to country' and cleansing ceremony was led by local indigenous leader Jack Buckskin.

About Agilex Biolabs

Agilex Biolabs is Australia's leading provider of bioanalytical services and toxicology studies supporting preclinical and clinical drug development. With over 25 years of specialized experience and a rapidly growing suite of full-service offerings, Agilex equips biopharma companies from United States, Asia-Pacific, and European regions with reliable, defendable data as they advance novel therapeutics through the development pipeline. By combining specialized expertise, technological innovation, and a 25-year track record, the Agilex team has successfully supported hundreds of preclinical and clinical trials from around the world. Agilex Biolabs is headquartered in Adelaide, South Australia, with additional laboratory sites in Queensland. For more information, visit https://www.agilexbiolabs.com/

Social Links
Twitter: https://twitter.com/AgilexBiolabs
LinkedIn: https://linkedin.com/agilex-biolabs
YouTube: https://www.youtube.com/channel/UCK8yK3JxXni6QhiorMUIyLA

Media Contact
Janki Patel, Marketing Associate, Agilex Biolabs
E-Mail: janki.patel@agilexbiolabs.com
Website: https://www.agilexbiolabs.com/

SOURCE: Agilex Biolabs



トピック: Press release summary
Source: Agilex Biolabs

セクター: Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Agilex Biolabs Related News
May 12, 2022 15:00 HKT/SGT
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
Oct 19, 2021 15:00 HKT/SGT
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
Sept 24, 2021 17:00 HKT/SGT
애질렉스 바이오랩스, 사이트라인 어워드(Citeline Award)의 코로나19 백신 독성학 임상 전 연구 부문 최종 수상 후보로 선정
Sept 24, 2021 09:00 HKT/SGT
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
Sept 24, 2021 09:00 HKT/SGT
Agilex Biolabs 被宣布为 COVID-19 疫苗毒理学临床前研究的 Citeline 奖决赛选手
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575